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Linear gramicidin activates neutrophil functions and the activation 
is blocked by chemotactic peptide receptor antagonist 
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The activation of functional responses in rabbit peritoneal neutrophils by gramicidin and the chemotactic pcptide, N- 
formyl-methionyl-leucyl-phenylalanine m thyl ester, was studied. Gramicidin activated superoxide generation, lysosomal 
enzyme release and a decrease in fluorescence of chlortetracycline-loaded cells, as for the chemotactic peptide. The 
maximum intensities of the responses by gramicidin were lower than that by chemotactic peptide. Responses by both 
these peptides could be inhibited by r-butyloxycarbonyl-methionyl-leucyl-phenylalanine, a chemotactic peptide receptor 
antagonist. Gramicidin gave responses at low doses comparable to that of the chemotactic peptide. 
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1. INTRODUCTION 
N-Formylated peptides bind to receptor sites on 
the neutrophils and activate functional responses 
including chemotaxis, lysosomal enzyme release 
and superoxide anion generation [l-3]. Maximum 
activity was observed with N-formyl-methionyl- 
leucyl-phenylalanine [ 11. Peptides having amino 
acids with aliphatic side chains, like valine and 
isoleucine, in place of methionine at position 1 
have fairly high activity [3]. The N-protected 
tripeptide, BMLP is an antagonist of the 
chemotactic peptide receptor [3]. 
Gramicidin A, B and C are linear pentadecapep- 
tide ethanolamide antibiotics having a formyl 
group at the amino-terminus valine or isoleucine 
[4-61. Gramicidin forms trans-membrane channels 
for monovalent cations [7-91. This property can 
result in depolarisation of membrane potential in 
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biological membranes treated with gramicidin [lo], 
including that of neutrophils [ 11,121. 
This report presents data which show that 
gramicidin activates neutrophil functions and 
chemotactic peptide receptor antagonist inhibit 
that activation. 
2. MATERIALS AND METHODS 
2.1. Materials 
Gramicidin from Bacillus brevis (Dubos), chlortetracycline 
HCl, cytochalasin B and all enzyme substrates were from 
Sigma. FMLP and BMLP were kindly provided by Professor P. 
Balaram. The commercial preparation of gramicidin, as a mix- 
ture of A, B and C, was used directly: the molecular mass of 
which was taken to be 1880 Da. 
2.2. Preparation of rabbit neutrophils 
Rabbit peritoneal exudate neutrophils were collected 4 h after 
injection of 0.1% glycogen in normal saline into the peritoneal 
cavity [13]. Cells were washed by centrifugation and suspended 
in buffer containing 17 mM Hepes, 122 mM NaCl, 5 mM KC1 
and 5 mM glucose. Ca” and Mg*+ were added as required in 
the assay. 
2.3. Measurement of superoxide anion generation 
Reduction of ferricytochrome cby superoxide anion was used 
to measure the generation of superoxide by neutrophils as 
described [14], with minor modifications. 1.5 x lo6 cells in 2 ml 
of buffer containing 1 mM Ca’+, 1 mM Mg*+ and 
0.625 mg/ml of horse heart cytochrome c were stirred and in- 
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cubated at 37°C in a Shimadzu UV-2lOA spectrophotometer. 
Cells were pretreated with 4 /g/ml of cytochalasin B for 4 min 
before addition of the test samples. Absorbance changes were 
measured at 550 nm. 
2.4. ASSQY of ~JJSOSO~Q~ enzyme release 
Lysosomal enzyme release assay was done at 37°C in 1 ml of 
buffer containing 1 x lo6 cells, 1 mM Mg’+ and 1 mM Ca*+. 
Cells were pretreated with cytochalasin B and test samples were 
added. Cells were separated by centrifugation and enzyme ac- 
tivities assayed in the supernatant. Lysozyme activity was 
measured by absorbance change in a suspension of Micrococcus 
lysodeikticus at 450 nm [ 151. &Glucuronidase was assayed by 
estimating the release of phenol-phthalein &glucuronide at 
550 nm [16]. Lactate dehydrogenase, a cytoplasmic enzyme, 
was assayed by measuring the change in absorbance at 340 nm 
in a solution containing NADH and pyruvate [17]. Total en- 
zyme activities in the cells for all the three enzymes were 
measured after lysing the cells in 0.2% Triton X-100. 
Id.4 
2.5. Measurement of chlortetracydine fluorescence response 
Fluorescence changes, in response to various stimulants in 
neutrophils loaded with chlortetracycline was measured as 
described elsewhere [18], with some modifications. Cells at 5 x 
106/ml were incubated at 37°C for 30 min in buffer containing 
100 PM chlortetracycline and 0.5 mM CaZC but no Mg”. Cells 
were pelleted by centrifugation, then washed once in buffer 
without Ca2’, Mg2+ and chlortetracycline, and resuspended in 
the same buffer. These cells, suspended at 2.5 x 106/ml in buf- 
fer without Ca2+ and Mg*+, were stirred and incubated at 37°C 
in a Perkin Elmer MPF-44A fluorescence spectrophotometer 
for the assay. The excitation and emission wavelengths were 
380 nm and 560 nm, respectively. 
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Fig.1. Superoxide generation by neutrophils in response to 
FMLP and gramicidin, and the inhibition by BMLP. (a,c) 
FMLP and gramicidin (GR) alone; (b,d) FMLP and gramicidin 
response of cells pretreated with 10 PM BMLP for 2 min. 
3. RESULTS 
enzymes by neutrophils in response to FMLP and 
gramicidin. The responses by gramicidin were of 
lower intensity than that by FMLP. 20 PM BMLP 
Fig.1 shows superoxide anion generation by 
neutrophils in response to various stimuli. The 
response started after a delay of 20-30 s following 
the addition of samples. FMLP gave an optimum 
response at 10 nM. The 10 nM and 1 nM FMLP 
responses were inhibited to varying degrees by 
10 PM BMLP. Gramicidin gave a maximum 
response at 10 nM and that response was much 
lower in intensity than that by FMLP. There was 
complete inhibition of the 10 nM gramicidin 
response by 10 pM BMLP and 1 ,uM gramicidin 
partially overcame that inhibition. Thus 
gramicidin gave a superoxide response at fairly low 
concentrations comparable to that of FMLP but 
BMLP inhibited the gramicidin response much 
more efficiently than it inhibited the FMLP 
response. The intensity of the responses by 
gramicidin were lower than that by FMLP. 
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Fig.2. Lysosomal enzyme release by neutrophils in response to 
FMLP and gramicidin, and the inhibition by BMLP. Values 
expressed as percentage of total activity released from detergent 
lysed cells. Neutrophils were incubated with FMLP (0,o) or 
gramicidin (0, n ) in the presence (0, n ) or absence (0, 0) of 
Fig.2 shows the results of secretion of lysosomal 20 PM BMLP. 
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FMLP 4. DISCUSSION 
10% RELATIVE 
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Experiments reported in this work clearly show 
that linear gramicidin activates functional 
responses in neutrophils. The presence of formyl 
group at the amino-terminus valine/isoleucine of 
gramicidin [4-61 suggests a structure compatible 
with chemotactic peptide receptor binding. 
Another possible mode of activation is by the abili- 
ty of gramicidin to depolarise membrane potential 
in cells, including neutrophils [lo-121. The obser- 
vation that all the three responses described for 
gramicidin in neutrophils can be inhibited by 
chemotactic peptide receptor antagonist, suggests 
that gramicidin acts through this receptor and not 
by membrane depolarisation. 
Fig.3. Fluorescence decrease in chlortetracycline-loaded 
neutrophils in response to FMLP and gramicidin. (a,c) FMLP 
and gramicidin (CR) alone; (b,d) FMLP and gramicidin 
response, respectively, of cells pretreated with 10 PM BMLP for 
2 min. 
inhibited the responses by gramicidin much more 
efficiently than the responses by FMLP. The lac- 
tate dehydrogenase activities in all assays were 
close to that of the blank (less than 4% of total ac- 
tivity) . 
Fluorescence decrease in response to FMLP and 
gramicidin were studied in chlortetracycline- 
loaded neutrophils (fig.3). The fluorescence 
response started within 4 s of the addition of 
FMLP. But there was a delay of about 30 s in the 
onset of responses by 1 nM gramicidin. 
Gramicidin gave a maximum response which was 
of lower intensity than the maximum response of 
FMLP. Dose-related responses were similar with 
both the peptides, 10 nM giving an optimum 
response and no response at 0.1 nM. In the 
presence of 10 PM BMLP, 1 nM FMLP and 
10 nM gramicidin did not give a response. Inhibi- 
tion by BMLP of the gramicidin response was 
much better than the inhibition of the FMLP 
response. 
Although gramicidin and FMLP gave responses 
at similar concentrations, there were three dif- 
ferences noted in their responses. (i) The maximum 
intensity of the response by gramicidin is much 
lower than that by FMLP. (ii) BMLP appears to 
inhibit gramicidin response more efficiently than 
FMLP response. (iii) There was a greater delay in 
the onset of responses by 1 nM gramicidin and by 
100 nM gramicidin in the presence of 10 /rM 
BMLP (fig.3c and d). This delay was absent in the 
case of FMLP. It is not possible to explain these 
observations with the available data. The alter- 
nating D- and L-amino acids, the larger size of 
gramicidin compared to FMLP and their relatively 
high lipid solubility may be contributing factors. 
The higher molecuIar mass of gramicidin and their 
tendency to dimerize in lipid bilayers [19] to form 
NHz-terminal to NH2-terminal dimers [20] might 
restrict their mobility and the accessibility of for- 
my1 groups in membranes. These may affect the 
ability of gramicidin to interact with the chemotac- 
tic peptide receptors. 
Decrease in chlortetracycline fluorescence 
measures release of membrane bound calcium in- 
side cells [ l&21-23]. Presence or absence of 1 mM 
Ca2+ or 1 mM EGTA in the absence of added Ca2+ 
in the extracellular medium do not produce any 
significant changes in the fluorescence response 
(not shown). The assay reported here was done in 
the absence of extracellular Ca2+. Gramicidin has 
ionophoretic activity only for monovalent cations 
[7-91 and is not a Ca2+ ionophore [8]. The 
response by gramicidin can be completely blocked 
by BMLP. Hence fluorescence response is not due 
141 
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to the ionophoretic activity of gramicidin but due 
to flux of Ca2+ in the intracellular pools, mediated 
through the membrane receptor. 
Tyrothricin, an antibiotic preparation from 
Bacillus brevis, contains about 20% gramicidin 
and 80% tyrocidin. It has been used therapeutical- 
ly as a local antibiotic on infected surface ulcers 
and wounds. It is toxic when given parenterally 
and on fresh wounds [24,25]. On the basis of the 
above results, one of the potential toxicities of 
gramicidin may be due to activation of neutrophil 
functions resulting in inflammation at the site of 
application. 
Chemotactic peptide receptors have been 
demonstrated in other cell types like macrophages 
and spermatozoa 126,271, in addition to 
neutrophils. Hence caution should be taken in in- 
terpreting the results in such cells when gramicidin 
is used for depolarisation of membrane potential 
by its channel properties. 
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